LRRK2 A419V Is Not Associated with Parkinson’s Disease in Different Chinese Populations

Yih Ru Wu¹*, Louis C. Tan², Xiaoli Fu³, Chiung Mei Chen¹, Wing Lok Au², Ling Chen³, Yi Chun Chen¹, Kumar M. Prakash², Yifan Zheng³, Guey-Jen Lee-Chen⁴, Yi Zhao², Jin-Sheng Zeng³, Eng King Tan²,⁵, Zhong Pei³

¹Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Linkou, Taiwan, ²Singapore General Hospital, National Neuroscience Institute, Singapore, Singapore, ³Department of Neurology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, ⁴Department of Life Science, National Taiwan Normal University, Taipei, Taiwan, ⁵Duke-National University of Singapore, Graduate Medical School, Singapore, Singapore

Abstract

It has been suggested that a common LRRK2 polymorphic variant (A419V (rs34594498 C>T)) may be a risk factor among Asians (especially in Taiwan). In this study, we examined this variant in a larger and independent Taiwan cohort. We found the frequency of the variant (A419V) to be very rare in our Taiwan PD and controls (70.6%). Further studies were conducted in two other Chinese populations (Singapore and China), comprising of a total of 3004 subjects including 1517 PD patients and 1487 control subjects. However, our multi-center Chinese study revealed that the frequency of the variant was rare (70.4%) and was not associated with risk of PD, suggesting that the variant is not a major risk factor for PD among Chinese, at least in our study population.

Citation: Wu YR, Tan LC, Fu X, Chen CM, Au WL, et al. (2012) LRRK2 A419V Is Not Associated with Parkinson’s Disease in Different Chinese Populations. PLoS ONE 7(7): e36123. doi:10.1371/journal.pone.0036123

Editor: Christian Wider, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland

Received March 13, 2012; Accepted March 26, 2012; Published July 10, 2012

Copyright: © 2012 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grant NSC98-2628-B-182A-001-MY3 from the National Science Council, Executive Yuan; grant from National Medical Research Council, Duke-NUS Graduate Medical School, Singapore Millennium Foundation; grants from the National Basic Research Program of China (973 Program) (No. 2011CB510000) and grants from the Guangdong Science and Technology Foundation (No. 2010B050700018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: yihruwu@adm.cgmh.org.tw

Introduction

Several pathogenic genes and susceptibility loci of Parkinson’s disease (PD) have been identified in both familial and sporadic cases in the last decade [1]. Mutations in the leucine-rich repeat kinase 2 gene (LRRK2/PARK8) were reported as a cause of PD in families with an autosomal dominant pattern of inheritance by two groups in 2004 [2,3]. There has been considerable interest in LRRK2, probably due to the discovery of a common mutation (G2019S) [4] in many countries and its high frequency (30–40%) among Ashkenazi Jews and north African Arabs as well as the discovery of common risk variants (G2385R and R1268P) among Arabs–Berber, and identified a common polymorphic risk variant (A419V) in 3 Asian cohorts (1376 Asian patients and 962 controls) [7]. Remarkably, the variant A419V conferred an increased risk in developing PD with an odds ratio of >7.0 in one cohort consisting of ethnic Chinese from Taiwan [7]. Currently, it is unclear whether this observation is specific to ethnic Chinese or this risk factor applies to Asians in general.

Results

The mean age at onset of PD in the three groups (Taiwan, Singapore and China) was 63.0±11.2, 64±10, 60.1±11.0 years, and the mean age of control subjects at recruitment was 60.1±11.2, 59.9±9.8 and 60.2±13.2 years. The gender of the patient and control groups was matched in each cohort. All three cohorts showed similar minor allele frequency (MAF) of the SNP in the normal population (the frequency of 200 cases in Singapore was previously reported to be 0.4%) [8], but a marginal higher MAF was found in the PD group of the China cohort (Table 1).

Discussion

Our multi-center Chinese study, with a much larger sample size (>3000) than the previously reported Taiwan Chinese cohort (about 700) or combined mixed Asian cohort (>2300), showed the frequency of the variant was rare (70.4%) and was not associated with risk of PD, suggesting that the variant is not a major risk factor for PD among Chinese, at least in our study population.

It’s intriguing why the results of ours and the other Taiwanese group in the multi-center study were markedly different [7]. Possible reasons may be due to very low MAF (0.33–1.9%) of the exonic variant (A419V), natural sampling variation, and population heterogeneity. The potential biological functions for this SNP are unknown. A419V is near the N-terminal region of the LRRK2 protein and maybe functionally relevant to disease development, or it is in linkage disequilibrium with a non coding variant or the actual causative variant. As new loci susceptible to different complex diseases are continuously being discovered in genome-wide association and whole-genome sequencing studies, the results of our study demonstrate the importance of revisiting loci at which
common or rare variants have been identified. It is possible that the A419V variant is a risk factor in only selected Asian populations or even subset of Chinese, unlike G2385R which has been consistently seen across all Chinese populations [5]. Other factors such as gene-gene, gene-environmental factors may be confounding variables to explain the divergent associations observed. Further multi-center studies will be warranted to characterize the frequency of the variant in different populations, in order to better decipher its contribution to the disease pathogenesis.

Materials and Methods

Ethics Statement

All subjects gave written informed consent for this study under a protocol approved by local hospital internal ethics and scientific boards. (Chang Gung Memorial Hospital internal ethics and scientific boards for the Taiwanese cohort, Singapore General Hospital and Singhealth ethics and scientific boards for the Singapore cohort and The First Affiliated Hospital internal ethics and scientific boards, Sun Yat-Sen University for the China cohort).

Subjects

The diagnosis of PD was based on the UK PD Society Brain Bank clinical diagnostic criteria (more than one affected relative was excluded). Unrelated healthy adult volunteers matched for age, gender, ethnic origin, and area of residences were recruited as controls. We first recruited 485 PD patients and 494 control subjects in the Taiwanese Cohort and we found the frequency of the variant (A419V) to be very rare (~0.6%). The subjects examined here did not overlap with the Taiwanese population included in the study performed by Ross et al [7]. Therefore, additional replications were conducted in two other Chinese population (Singapore and China), comprising of a total of 3004 subjects including 1517 PD patients and 1487 control subjects subsequently to be analyzed.

Genotyping

TaqMan® Assays were used for SNP genotyping analysis in the Taiwanese cohort. Genotyping was carried out with mass spectrometric analysis using the Sequanom® and sequence analysis from Singapore, and direct sequence analysis in the China cohort.

Statistical Analyses

Chi square test was used to compare the frequency of the allele in both cases and controls. The genotypes of the case and controls followed the Hardy Weinberg equilibrium. Odds ratios and 95% confidence intervals were estimated. A free and open source software (OpenEpi) was used for the statistical analysis [9].

Acknowledgments

We thank the patients and controls for participating in this study.

Author Contributions

Conceived and designed the experiments: YRW EKT ZP. Performed the experiments: GJLC XF LC KMP Y. Zheng. Analyzed the data: Y. Zhao JSZ YCC LCT WLA. Contributed reagents/materials/analysis tools: CMC YRW EKT ZP. Wrote the paper: YRW EKT.

References

1. Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 12: 301–325.
2. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44: 595–600.
3. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601–607.
4. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, et al. (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 16: 237–242.
5. Tan EK, Peng R, Wu YR, Wu RM, Wu-Chou YH, et al. (2009) LRRK2 G2385R modulates age at onset in Parkinson’s disease: A multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet 150B(7): 1022–3.
6. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, et al. (2008) Analysis of Lrrk2 R1628P as a risk factor for Parkinson’s disease. Ann Neurol 64: 88–92.
7. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, et al. (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case–control study. Lancet Neurol 10: 898–908.
8. Tan EK, Peng R, Teo YY, Tan LC, Angeles D, et al. (2010) Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 31(5): 561–8.
9. Dean AG, Sullivan KM, Soe MM (2010) OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. able: www.OpenEpi.com Accessed 2012 Jun 18.